2BO Stock Chart & Stats
€1.80
-€0.06(-3.23%)
At close: 4:00 PM EDT
€1.80
-€0.06(-3.23%)
Day’s Range― - ―
52-Week Range€1.07 - €4.78
Previous CloseN/A
Volume0.00
Average Volume (3M)86.00
Market Cap
€53.09M
Enterprise Value€11.97
Total Cash (Recent Filing)€23.02M
Total Debt (Recent Filing)€3.21M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Nov 18, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding25,400,473
10 Day Avg. Volume0
30 Day Avg. Volume86
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.15Price Target Upside352.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces interest and refinancing pressure, preserving financial flexibility as Serina funds development. This strengthens resilience relative to a highly leveraged biotechnology company, although cash losses still require external funding.
POZ Platform And Lead CandidateA reusable drug-delivery platform could support multiple therapeutic programs and create partnering potential beyond one asset. SER-252 provides a focused development priority, while the platform offers a basis for longer-term pipeline expansion.
Experienced Board AdditionAdding a director with commercialization and financing experience may improve clinical, partnering and corporate decisions during a pivotal development phase. These capabilities are relevant to converting platform science into partnerships or future commercial execution.
Bears Say
No Current RevenueThe absence of current revenue confirms that Serina remains pre-commercial and dependent on successful clinical development before building operating scale. Deep losses also reduce earnings visibility and leave results highly exposed to development outcomes.
Persistent Cash BurnLarge cash outflows mean Serina cannot presently fund operations internally and must rely on financing or partnerships. Continued burn can constrain development choices and increase the risk that future capital is raised on unfavorable terms.
Equity Dilution RiskExpanded equity capacity improves access to capital but can materially dilute existing holders as new shares fund operations. The need for this flexibility also highlights the company’s dependence on external financing while it remains loss-making.
Serina Therapeutics News
2BO FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was €1.07 and its highest was €4.78 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is €53.09M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 77 days.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on Aug 13, 2026. The company reported -€0.475 earnings per share for the quarter, missing the consensus estimate of -€0.403 by -€0.073.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 25,400,473 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -€0.475 in its last earnings report, missing expectations of -€0.403. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in DE:2BO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Serina Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€8.15 (352.73% Upside)
€8.15 (352.73% Upside)
Insider Transactions
Bought Shares
Worth €8.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
188.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
2BO Stock 12 Month Forecast
Average Price Target
€8.15
▲(352.73% Upside)
Technical Analysis
Outlook Therapeutics
―
Skye Bioscience
―
Celularity
―
Barinthus Biotherapeutics
―
Jupiter Neurosciences, Inc.
―